CRYOLIFE INC

KENNESAW, GA · Medtech · Public

Preserved human cardiac and vascular tissues, surgical adhesives, sealants, prosthetic heart valves, and cardiac surgical devices

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cryolife.com

Sector: Medtech
Headquarters: KENNESAW, GA
Latest Form D: $20M, Sep 2020
Total capital: $63.1M

Federal grants: $2.8M; 18 awards · 1987–1997; 18× sector median 1 award
Private capital raised: $60.2M; 3 Form D · last Sep 2020; 73 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 3; 16 pending · first 2014; Rank in peer group#370 of 1112

Capital timeline

Latest events

Sep 2020Private capital raisedForm D · SEC · 3rd filing$20M
Jan 2016Private capital raisedForm D · SEC · 2nd filing$39M
Oct 2010Private capital raisedForm D · SEC · 1st filing$1.3M
Sep 1997Federal grantHealth and Human S · Phase II · Use Of Xenogenic Matrix As Vascular Bypass Conduit$435K
Sep 1997Federal grantHealth and Human S · Phase II · Use Of Xenogenic Matrix As Vascular Bypass Conduit$315K
Sep 1997Federal grantHealth and Human S · Phase I · Cryopreserved Arteries As Allograft Vascular Conduit$100K
Aug 1996Federal grantHealth and Human S · Phase I · Engineered Heart Valve--flow And Fibroblast Function$99K

Show 14 earlier federal awards

Sep 1995Federal grantHealth and Human S · Phase I · Xenogeneic Arterial Bypass Graft$73K
Sep 1995Federal grantHealth and Human S · Phase I · Bioadhesive For Surgery And Wound Repair$100K
Sep 1995Federal grantHealth and Human S · Phase I · Fascia Lata Xenograft For Acl Replacement$92K
Aug 1994Federal grantHealth and Human S · Phase I · Xenograft Heart Valves--biomechanics/collagen Structure$75K
Aug 1994Federal grantHealth and Human S · Phase II · Acellular Porcine Heart Valve Bioprostheses$501K
Aug 1994Federal grantHealth and Human S · Phase II · Acellular Porcine Heart Valve Bioprostheses$244K
Sep 1993Federal grantHealth and Human S · Phase I · Ultraviolet B Irradiation Of Allogeneic Veins$50K
Aug 1993Federal grantHealth and Human S · Phase II · Development Of A Fibrin Sealant Delivery Method$189K
Aug 1993Federal grantHealth and Human S · Phase II · Development Of A Fibrin Sealant Delivery Method$311K
Jul 1991Federal grantHealth and Human S · Phase I · Repopulation Of Xenograft Heart Valves With Fibroblasts$50K
May 1991Federal grantHealth and Human S · Phase I · Development Of A Fibrin Sealant Delivery Method$49K
Feb 1991Federal grantHealth and Human S · Phase I · Bone Marrow Cryopreservation With Antifreeze Peptides$49K
Sep 1988Federal grantHealth and Human S · Phase I · Cryopreservation Of Ligaments And Tendons$49K
Mar 1987Federal grantHealth and Human S · Phase I · Cryopreservation Of Venous And Arterial Tissue$50K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

283months

from CRYOLIFE INC’s first federal award to its first private round.

First federal award · Mar 1987: Health and Human S · $50K
First Form D · Oct 2010: $1.3M · 1st Form D
Awards before first raise: 18 awards

An association in public records, not a cause or a prediction.

Standing among 1112 peers

Line = median

Medtech · Device

Granted patents#370 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

ALBERT E. HEACOX, PH.D.Executive OfficerNamed in SEC Form D filings
Amy D HortonExecutive OfficerNamed in SEC Form D filings
Daniel J. BevevinoDirectorNamed in SEC Form D filings
DAVID M. FRONKExecutive OfficerNamed in SEC Form D filings
David C GaleExecutive OfficerNamed in SEC Form D filings
Dennis B. MaierExecutive OfficerNamed in SEC Form D filings

Show all 31 people

D Ashley LeeExecutive OfficerNamed in SEC Form D filings
D. ASHLEY LEEExecutive OfficerNamed in SEC Form D filings
Franz Peter BartholdExecutive OfficerNamed in SEC Form D filings
GERALD B. SEERYExecutive OfficerNamed in SEC Form D filings
HARVEY D. MORGANDirectorNamed in SEC Form D filings
JAMES S. BENSONDirectorNamed in SEC Form D filings
James W. BullockDirectorNamed in SEC Form D filings
Jean F HollowayExecutive OfficerNamed in SEC Form D filings
Jeffrey H. BurbankDirectorNamed in SEC Form D filings
JEFFREY W. BURRIS, ESQ.Executive OfficerNamed in SEC Form D filings
J Patrick MackinExecutive Officer, DirectorNamed in SEC Form D filings
J. Patrick MackinExecutive Officer, DirectorNamed in SEC Form D filings
John E. DavisExecutive OfficerNamed in SEC Form D filings
Jon W SalvesonDirectorNamed in SEC Form D filings
Marna P. BorgstromDirectorNamed in SEC Form D filings
Matthew A. GetzExecutive OfficerNamed in SEC Form D filings
Michael S. SimpsonExecutive OfficerNamed in SEC Form D filings
Ronald C ElkinsDirectorNamed in SEC Form D filings
RONALD C. ELKINS, M.D.DirectorNamed in SEC Form D filings
Ronald D. McCallDirectorNamed in SEC Form D filings
RONALD D. MCCALL, ESQ.DirectorNamed in SEC Form D filings
Scott B CappsExecutive OfficerNamed in SEC Form D filings
STEVEN G. ANDERSONExecutive Officer, DirectorNamed in SEC Form D filings
Thomas F AckermanDirectorNamed in SEC Form D filings
William R MatthewsExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 19

Oct 21, 2025GrantedHuman Placental Tissue Graft Products, Methods, And ApparatusesUSPTOUS 12,447,231
Sep 26, 2019PendingHuman Placental Tissue Graft Products, Methods, And ApparatusesUSPTOApplication 16068210
Aug 20, 2015PendingMethod Of Treatment Of Dissected Lymph Node And/or VesselUSPTOApplication 14625091

Show all 19 patent records

Human Placental Tissue Graft Products, Methods, And ApparatusesOct 21, 2025 · US 12,447,231Granted
Human Placental Tissue Graft Products, Methods, And ApparatusesSep 26, 2019 · Application 16068210Pending
Method Of Treatment Of Dissected Lymph Node And/or VesselAug 20, 2015 · Application 14625091Pending
Human Central Venous Anatomy Demonstration DeviceApr 14, 2015 · US D,726,818Granted
Tissue Implants For Implantation And Methods Of Preparing The SameNov 11, 2014 · US 8,883,408Granted
Methods For Preparing Tissue ImplantsSep 18, 2014 · Application 14200422Pending
Human Placental Tissue Graft Products, Methods, And ApparatusesApplication PCTUS2017012384Pending
Method Of Treatment Of Dissected Lymph Node And/or VesselApplication PCTUS2015016342Pending
Systems And Methods For A Fluid Carrying Conduit Of A Vascular Access SystemApplication PCTUS2014049547Pending
Central Nervous System Localized Hypothermia Apparatus And MethodsApplication PCTUS2019023556Pending
Vascular Access System With ConnectorApplication PCTUS2014046630Pending
Methods For Preparing Tissue ImplantsApplication PCTUS2014021625Pending
Method Of Treatment Of Dissected Lymph Node And/or VesselApplication 61941011Pending
Methods For Preparing Tissue ImplantsApplication 61792842Pending
Applicator Delivery Tip ExtensionApplication PCTUS2011025940Pending
Bioburden-reducing Antibiotic Composition And Method Of UseApplication PCTUS2010026923Pending
Human Placental Tissue Graft Products, Methods, and ApparatusesApplication 62327857Pending
Expandable Foam-like Biomaterials And MethodsApplication PCTUS2001042987Pending
Human Placental Tissue Graft Products, Methods, And ApparatusesApplication 62276655Pending

Codetta Bio Inc.Similar federal contract value in Medtech · null in contracts
PASCAL MEDICAL CORPORATIONSimilar federal contract value in Medtech · null in contracts
COSMOSID, INC.Similar federal contract value in Medtech · null in contracts
Native Cardio, Inc.Similar federal contract value in Medtech · null in contracts
Valar Labs, Inc.Similar federal contract value in Medtech · null in contracts
PELVA HEALTH CORPORATIONSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.